2 enrolling by invitation. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Vutrisiran - Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Enrolling by invitation | Alnylam Pharmaceuticals | 700 | 2024-12-03 | 2026-10-21 |
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Eplontersen - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Enrolling by invitation | Ionis Pharmaceuticals, Inc. | 1400 | 2022-11-30 | 2026-04-17 |
Amyloidosis, Hereditary, Transthyretin-Related (1) · Cardiomyopathies (1)
Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Proteostasis Deficiencies (2) · Cardiovascular Diseases (1) · Heart Diseases (1)
eplontersen (1)
Alnylam Pharmaceuticals (1) · Ionis Pharmaceuticals, Inc. (1)
Argentina (2) · Austria (2) · Belgium (2) · Brazil (2) · Czechia (2) · Denmark (2) · France (2) · Italy (2) · Portugal (2) · Spain (2) · Sweden (2) · United Kingdom (2) · United States (2) · Australia (1) · Canada (1)